Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

68 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-11-13

Study Completion Date

2026-03-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research trial studies genetic profiles in blood and tumor samples from patients with estrogen receptor positive and HER2 negative breast cancer that has spread to other places in the body who are receiving palbociclib and endocrine therapy. Examining the genetic changes associated with the cancer and comparing the genetic material from the cancer tissue with the genetic material found in the blood may help doctors to develop customized treatment for breast cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

NCT03628066

Breast Cancer

COMPLETED PHASE2

Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer

NCT00899509

Breast Cancer

COMPLETED

Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer

NCT01334021

Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 +20 more

ACTIVE_NOT_RECRUITING PHASE2

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

NCT05826964

Breast Cancer ER-positive Breast Cancer HER2-negative Breast Cancer +1 more

ACTIVE_NOT_RECRUITING PHASE2

A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

NCT02296801

Breast Cancer Breast Carcinoma Breast Tumors

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Breast Carcinoma Locally Advanced Breast Carcinoma Metastatic Breast Carcinoma Recurrent Breast Carcinoma Stage III Breast Cancer AJCC v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ancillary-Correlative (genetic profile analysis)

Patents undergo collection of blood and stool samples at baseline, 7 days after letrozole monotherapy treatment, and at completion of each cycle, urine samples at baseline and completion of each cycle, and saliva samples at baseline. Patients also undergo collection of blood and urine samples at disease progression. Biopsy samples are analyzed for genetic profile via genome sequencing and RNA sequencing. Biopsy samples are also used for the generation of xenograft mice model.

Biopsy

Intervention Type PROCEDURE

Undergo tumor biopsy

Biospecimen Collection

Intervention Type PROCEDURE

Undergo collection of blood, urine, stool, and saliva

Laboratory Biomarker Analysis

Intervention Type OTHER

Correlative studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biopsy

Undergo tumor biopsy

Intervention Type PROCEDURE

Biospecimen Collection

Undergo collection of blood, urine, stool, and saliva

Intervention Type PROCEDURE

Laboratory Biomarker Analysis

Correlative studies

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BIOPSY_TYPE Bx

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women who have disease that is amenable to biopsy and agree to undergo a standard of care and /or research biopsy

* Note: If a standard of care biopsy was recently obtained =\< 2 months of pre-registration, eligible patients should agree to a research biopsy of recurrent or metastatic breast cancer prior to the start of protocol treatment to collect additional core samples for research purposes
* Patients must satisfy one of the following criteria for prior therapy:

* First line setting: No prior endocrine therapy in the metastatic setting with no more than one prior line of chemotherapy in the advanced/metastatic setting
* Second line setting: Progression on one prior line of endocrine based therapy monotherapy either in the adjuvant or advanced/metastatic setting; either one or two prior lines of chemotherapy in the advanced setting are allowed
* Note: Patients receiving bisphosphonate or denosumab therapy prior to registration may continue at the same intervals used prior to study registration
* First line therapy setting only: The intention to begin palbociclib and letrozole as treatment for locally advanced or metastatic breast cancer
* Second line therapy setting only: The intention to begin palbociclib and fulvestrant as treatment for metastatic breast cancer (after progression on first line endocrine therapy)

* Note: Patients who are to receive second line endocrine therapy are allowed to remain on their most recent treatment (tamoxifen or an aromatase inhibitor during the pre-registration period as well as after registration while awaiting insurance approval for the use of palbociclib
* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria or bone only disease are eligible.

* Note: Those patients with both non-measurable disease and bone metastases are eligible
* Note: Patients are not allowed to begin a new systemic anti-cancer therapy during pre-registration with the exception of bisphosphonate or denosumab; palliative radiation to lesions that will not be biopsied or used for assessing disease response (target lesions) is allowed during pre-registration
* No current evidence of visceral crisis
* History of central nervous system metastasis are allowed provided they have been treated (i.e., surgery, radiation, and/or radiosurgery) \>= 12 weeks prior to pre-registration and have stable neurologic function, including no requirement for medication(s) to control symptoms for at least 2 weeks; Note: patients with known leptomeningeal disease are not eligible
* Women who are premenopausal must agree to begin or continue an leutinizing hormone releasing hormone (LHRH) agonist (goserelin preferred)

* NOTE: A woman is considered premenopausal if menses has occurred in the last 12 months prior to preregistration and both serum and follicle stimulating hormone (FSH) levels are not in the laboratory's reference range for postmenopausal females
* Eastern Cooperative Oncology Group (ECOG) performance status: 0, 1, or 2
* Able to swallow oral formulation of drugs
* Signed and dated informed consent document for study participation
* Willing to submit tissue, blood, stool, and saliva and urine for required correlative research

* Histologic confirmation from the pre-registration biopsy of either locally advanced or metastatic breast cancer that is ER-positive and HER2 -negative

* Note: ER-positive disease is defined as \>= 10% nuclear staining; HER2-negative disease per American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, one of the following must apply:

* 0 or 1+ by immunohistochemistry (IHC) and not amplified by in situ hybridization (ISH)
* 0 or 1+ by IHC and ISH not done
* 2+ by IHC and not amplified by ISH or
* IHC not done and not amplified by ISH
* Absolute neutrophil count (ANC) \>= 1500/mm\^3 (=\< 14 days prior to registration)
* Platelet count \>= 100,000/mm\^3 (=\< 14 days prior to registration)
* Hemoglobin \>= 9.0 g/dL (=\< 14 days prior to registration)
* Total bilirubin =\< 1.5 x upper limit of normal (ULN), (=\< 3 x ULN if Gilbert's disease) (=\< 14 days prior to registration)
* Aspartate transaminase (AST) =\< 3 x ULN (=\< 5 x ULN if liver metastases present) (=\< 14 days prior to registration)
* Creatinine =\< 1.5 x ULN (=\< 14 days prior to registration)
* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
* Toxicities related to all prior anticancer therapies must have resolved or stabilized, apart from alopecia and peripheral neuropathy; Note: Peripheral neuropathy which has resolved to =\< grade 2 toxicity is acceptable

Exclusion Criteria

* History of metastatic ER negative or HER2 positive breast cancer
* Prior treatment in the metastatic setting with everolimus, or any agent whose mechanism of action is to inhibit the PI3K-mTOR pathway
* Uncontrolled intercurrent illness including, but not limited to:

* Ongoing or active infection
* Symptomatic congestive heart failure
* Unstable angina pectoris
* Uncontrolled symptomatic cardiac arrhythmia
* Uncontrolled hypertension (defined as blood pressure \> 160/90)
* Other active second malignancy other than non-melanoma skin cancers =\< 3 years of pre-registration; Note: a second malignancy is not considered active if all treatment for that malignancy is completed and the patient has been disease-free for =\< 3 years prior to pre-registration
* Prior hematopoietic stem cell or bone marrow transplantation =\< 3 years of pre-registration
* Known hypersensitivity to palbociclib, letrozole, fulvestrant, goserelin (if applicable) or to any of their excipients
* Known to be pregnant and planning to continue nursing

* No tumor identified on biopsy or insufficient tumor cells to obtain ER or HER2 status
* Any of the following therapies prior to registration:

* Chemotherapy =\< 2 weeks
* Immunotherapy =\< 2 weeks
* Biologic therapy =\< 2 weeks
* Monoclonal antibodies =\< 2 weeks

* Note: Denosumab is exempt from this requirement and can be started at any time prior to initiation of palbociclib and letrozole/fulvestrant without the need to delay protocol therapy
* Radiation therapy =\< 2 weeks

* Note: Palliative radiation therapy to lesions that will not be biopsied for this study or used for assessing disease response (target lesions) is permitted during the pre-registration period and does not count towards the 2 week window
* Anti HER2 or other "targeted" therapy =\< 2 weeks
* The following patients are not eligible

* Pregnant women
* Nursing women
* Women of childbearing potential who are unwilling to employ adequate contraception
* Women who have already commenced treatment with an aromatase inhibitor (first line setting) or fulvestrant (second line setting) prior to screening for this study or any prior palbociclib

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No